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Abstract  SA Fam Pract 2010;52(1):69-71
Background: Atopic eczema is a common skin condition. It has the potential to severely impair quality of life in affected children. Pimecrolimus is 
currently registered for mild-moderate eczema but in clinical practice children with more severe disease are often treated with this therapy in an 
attempt to find a safe addition to long-term topical corticosteroid usage. The aim of this study was to test the value of pimecrolimus in improving 
quality of life in children with severe atopic eczema.
Methods: This a single site, phase 4, non-randomised, open label trial of pimecrolimus use in children aged 4 months to 12 years living with 
moderate to very severe atopic eczema. The study was conducted at Steve Biko Academic Hospital. Patients with unsatisfactorily controlled disease 
despite conventional topical therapy, adequate use of emollients, allergen avoidance and non-pharmacological skin hygiene were enrolled. A Parent 
Index Quality of Life Questionnaire was completed by parents before and three months after using pimecrolimus. 
Results: A total of 24 patients were recruited, 20 of whom completed the study. Ninety per cent of patients had co-morbid asthma and allergic 
rhinitis. The Parent Index Quality of Life demonstrated a mean 33% score improvement after the use of pimecrolimus. There was an attendant 
reduction in cost of therapy to these patients.
Conclusions: Pimecrolimus usage should be extended to patients with more severe atopic eczema as the improvement in quality of life is important 
and demonstrable.
 Peer reviewed. (Submitted: 2009-04-10, Accepted: 2009-07-04). © SAAFP 
Introduction
Atopic eczema is a common skin condition. Most cases occur in young 
children (70% in children in the first year of life and 90% by the fifth 
year).1,2 There is currently little data for atopic eczema prevalence in 
South Africa. However, the International Study of Asthma and Allergy in 
Children (ISAAC) phase 1 and phase III studies reported the prevalence 
of atopic eczema to be 11.8% and 19.4% respectively in Cape Town 
schoolchildren.3,4 Worldwide the prevalence of atopic eczema has 
increased in recent times in line with other atopic diseases, that is asthma 
and allergic rhinitis. Atopic eczema is typically outgrown at puberty.5
It is a disease of exacerbations and remissions with associated trigger 
factors such as foods, infections and environmental factors. Risk factors 
for the atopic diathesis proposed, include rural to urban migration, 
increased use of antibiotics and western lifestyle. These are related to the 
hygiene hypothesis with a decrease in TH1 response and enhancement 
of TH2 responses.5 
Clinically the diagnosis of atopic eczema is made when there is a 
pruritic skin rash, positive family history of atopy, early onset and typical 
localisation of skin lesions according to age, stigmata for atopy and/or 
IgE mediated sensitisation.3 Atopic eczema‘s typical distribution is face, 
scalp and extensor surfaces in infants with sparing of the nappy area, 
and flexural surfaces and ankles in older children. For all age groups dry 
skin is common. Lichenification occurs if the rash is long standing. 
The other important, and much neglected, component of atopic eczema 
is impaired quality of life. Direct effects such as misery, lethargy and 
depression are seen in affected children. However, this term may include 
parents’ guilt on not being able to control the scratch/itch cycle, sibling 
rivalry due to attention shift to the affected sibling, loss of income due 
to repeated regular clinic visits for uncontrollable disease coupled with 
costs of both useful and useless interventions to control the disease. 
Psychological stress may occur in the whole family. 
Conventional therapy includes avoidance of precipitating factors, 
attention to clothing and bathing, emollients and topical steroids. Other 
modalities include treatment of infections and newer therapies such as 
calcineurin inhibitors. A potential problem with topical steroids is side-
effects which include skin atrophy, striae and potentially hypothalamic-
pituitary-adrenal suppression and Cushing’s syndrome due to systemic 
absorption. These side-effects, both real and perceived, can be worrying 
to parents and often result in poor adherence to therapy.
Pimecrolimus 1% cream (Elidel®) is a calcineurin inhibitor and an anti-
inflammatory ascomycin macrolactam derivative which selectively 
inhibits the production and release of pro-inflammatory cytokines and 
mediators in T cells and mast cells. Pimecrolimus binds with high affinity 
to macrophilin-12 and inhibits the calcium-dependent phosphatase 
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calcineurin. As a consequence, it inhibits T-cell activation by blocking the 
transcription of early cytokines. In particular, pimecrolimus inhibits, at 
nanomolar concentrations, interleukin-2, interferon gamma (Th1-type), 
interleukin-4 and interleukin-10 (Th2-type) cytokine synthesis in human 
T cells. 
In addition, pimecrolimus prevents the release of cytokines and pro-
inflammatory mediators from mast cells in vitro after stimulation by 
antigen and IgE. A major advantage of pimecrolimus is that it does not 
affect the growth of keratinocytes, fibroblasts or endothelial cell lines.6
Whalley D and colleagues2 have demonstrated the ability of pimecrolimus 
to improve quality of life in children with atopic eczema. A double-blind, 
controlled study conducted in 251 infants aged 3 months to 23 months 
with atopic dermatitis, by Kapp A and colleagues,7 demonstrated that 
the use of Elidel® reduced the incidence of flares, improved overall 
control, was safe and was well tolerated. Siegfried E and colleagues,8 in 
a double-blind, multicentre, randomised, vehicle controlled trial of 275 
children from 3 months to 11 years of age showed that early treatment 
of atopic dermatitis with pimecrolimus reduced the incidence of major 
flares, provided an effective steroid-sparing option and was efficacious 
and safe in the study subjects.
The current study was designed to address the value of pimecrolimus in 
improving quality of life of children with proven atopic eczema who have 
severe disease despite regular use of topical steroids. 
Methods
This was a three-month, single site, phase 4, non-randomised, open 
label trial to investigate the use of pimecrolimus (Elidel® 1% cream) in 
children with severe or very severe atopic eczema. The severity was 
assessed using the Investigator Global Assessment and only patients 
scoring 4 (severe disease: severe erythema, severe papulation/
infiltration) and 5 (very severe disease: severe erythema and papulation/
infiltration with oozing/crusting) being enrolled.9 All children, aged 
4 months to 12 years, between August and October 2007, who were 
seen regularly at the Allergy Clinic of Steve Biko Academic Hospital and 
who met these criteria, were enrolled. In addition, for inclusion into the 
study these patients had to have at least four out of five of the following: 
pruritis, stigmata for atopy, personal or family history of atopy, early 
onset or typical localisation of skin lesions according to age and IgE 
mediated sensitisation. In addition these patients had to have been using 
emollients, topical steroids, allergen avoidance where necessary and 
adequate non-medical interventions for at least six months. All children 
required at least one course of oral steroids in this period. 
Evidence from the literature suggests a controversial role for pimecrolimus 
in patients with severe atopic eczema.10 
Following the control of the current flare, these children were started 
on Elidel® cream. This was applied twice daily, after bathing, to affected 
sites. All children and parents were taught the correct administration 
technique and given a package insert as a reminder. Usual therapy with 
emulsifying ointment was continued but topical corticosteroids were 
discontinued for the study period. 
All subjects signed informed consent and assent if older than seven 
years of age.
PIQoL Assessment
The Parent Index Quality of Life (PIQoL) questionnaire was completed 
by parents on the first visit prior to using pimecrolimus. These were 
completed again at a follow-up visit at three months. The questionnaires 
were in English. At both visits those parents who had interpretation 
problems were assisted with translations into Sotho, Tswana or Zulu 
languages as needed. A total score out of 28 questions was given after 
each visit. PIQoL scores range from 0 to 28, the higher the score the 
poorer the quality of life.
Outcome measures
Comparison of quality of life scores before and after Elidel® use was 
performed. No clinical outcome measure was objectively made. 
Statistical analysis
This study employed a paired T-test to assess the probability of the 
significance of using PIQoL before and after using Elidel cream as a 
variable. The null hypothesis is quality of life before Elidel® use – quality 
of life after Elidel® use = 0. 
Approval to conduct this study was received from the University of 
Pretoria Ethics Committee.
Results
A total of 24 patients (12 females), meeting the enrolment criteria, were 
recruited. Four patients were lost to follow-up and did not complete 
the PIQoL questionnaire after study completion. These patients were 
excluded from the final analysis. Therefore, 20 subjects (11 female) 
completed the study. The subjects ranged in age from 4 months to 12 
years. One hundred per cent of patients had their eczema develop before 
the age of 5 years with 40% having an onset before 3 months of age, 
25% had onset between 3 months and 1 year and 30% before age 5. 
Slightly more than half the patients (55%) presented for medical help for 
the first time before age 5. Of the 20 patients who completed the study, 
12 (60%) had severe disease and 8 (40%) had very severe disease.
Fifty per cent of subjects had been using topical steroids daily for six 
months and 25% of patients had been using topical steroids daily for 
more than a year. Twenty five per cent of the subjects who had been on 
long-term topical steroids had developed striae and skin atrophy. All of 
these signs improved on the institution of pimecrolimus. No study drug 
side-effects were reported by the patients.
Skin prick testing was performed in all children (see Table I). Ninety per 
cent of subjects had co-existing asthma and/or allergic rhinitis.
Table I: Allergy test results for subjects. Skin prick test (n = 20) 
Allergen N (%)







Cow’s milk protein 2(10)
Negative test 2(10)
Some patients had more than one positive test.
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Figure 1 demonstrates the before and after intervention PIQoL scores 
for each individual. The average score before pimecrolimus was 61% 
(95% confidence interval 50.67338–70.82662). After therapy this 
improved to 28% (95% confidence interval 20.06153–36.09847). A 33% 
improvement was noted. (p < 0.0001). There was both a subjective and 
clinical improvement in eczema lesions after intervention. 
Discussion
Atopic eczema has a devastating impact on children and parents. On one 
hand, there is guilt and helplessness from parents when they are unable 
to control the scratch-itch cycle, poor quality of sleep, and adverse 
effects of treatment given to their children. On the other hand, direct 
and indirect costs for medications, investigations and transport are 
economically taxing especially to patients from a poor socio-economic 
background. Other indirect costs such as loss of income due to absence 
from work coupled with reduced productivity as well as intangible costs 
including loss of quality of life, pain and suffering and psychological 
maladjustments are also borne. 
Subjects enrolled in this study demonstrated an improvement in quality 
of life as assessed by the PIQoL questionnaire and clearing, or reduced, 
severity of skin lesions, after the use of the study medication. This quality 
of life improvement should be judged in these children on so-called 
‘maximal’ therapy for a severe disease. 
Pimecrolimus use has been associated with clinical and quality of life 
improvement in children with mild to moderate atopic eczema but 
studies in cases of severe disease are limited. This study suggests that 
children with more severe eczema will also benefit from this intervention. 
Certainly this form of therapy is a safe addition to other more adverse 
pharmacological therapies. 
Study limitations
The main study limitation is the small number of enrolled subjects. In 
addition, due to disease severity, it was deemed unethical to subject this 
group of patients to placebo therapy, hence each patient had to suffice 
as his/her own control with scores assessed prior to and after therapy. 
Conclusions
While cost-effectiveness by direct measurement could not be calculated, 
it must be remembered that direct cost is but one of the actual ‘cost’ 
determinants. Improved quality of life translates into cost-saving but is, 
in its own right, one of the most important measures in any chronic 
condition. We cannot and should not judge a therapy by its up-front 
direct monetary cost. The principle of cost-effectiveness is at stake.
References
1. Kemp AS, Varigos GA, Nolan TM, Su JC. Atopic eczema: Its impact on the family and financial costs. 
Arch Dis Child 1997;76;159–62.
2.  Whalley D, Huels J, Mckeena SP, van Assche D. Benefit of pimecrolimus on parents quality of life in 
treatment of paediatric atopic eczema. Paediatrics 2002;110:1133–6.
3. Manjra AI, du Plessis P, Weiss R, et al. Childhood atopic eczema consensus document. Current 
Allergy Clinical Immunology 2005;18:121–6.
4. Zar HJ, Ehrlich RI, Workman L, Weinberg EG. The changing prevalence of asthma, allergic 
rhinitis and atopic eczema in African adolescence from 1995 to 2002. Pediatr Allergy Immunol. 
2007;18:560–5.
5. Leung DYM, Sampson HA, Geha RS, Szefler SJ, editors. Paediatric Allergy principles and practice. St. 
Louis: Mosby;2003. 
6. Pimecrolimus (Elidel) package insert, Novartis pharmaceuticals 2006.
7. Kapp A, Papp K, Bingham A, et al. Long term management of atopic dermatitis in infants with topical 
pimecrolimus an anti-inflammatory drug. J Allergy Clin Immunol 2002;2:277–84.
8. Siegfried E, Korman N, Molina C, Kianifard F, Abrams K. Safety and efficacy of early intervention with 
pimecrolimus cream 1% combined with corticosteroid for major flares in infants and children with 
atopic dermatitis. J Dermatolog Treat. 2006;17:143–50. 
9.  Whan U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in long term 
management of atopic dermatitis in children. Pediatrics 2002;110:e2 http://paediatrics.
aapublications.org/cgi/content/abstract/110/1/e2 (Accessed 8 Jan 2008).
10. Spergel JM, Boguniewicz M, Paller AS, Hebert AA, Gallagher PR, McCormick C, et al. Addition 
of topical pimecrolimus to once-daily mid-potent steroid confers no short term therapeutic 
benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. Br J Dermatol 
2007;157:378–81.
11. Potter PC. Commentary on revised nomenclature for allergy released by EAACI Nomenclature Task 
Force. Current Allergy Clinical Immunology 2002;6:92–4.
12.  Morris A. ABC of Allergology. Current Allergy Clinical Immunology 2005;18:140–2.
13.  West DP. Topical calcineurin inhibitors in management of atopic dermatitis. http://www.medscape.
com/viewprogram/5896 (Accessed 8 Jan 2008).









Before Elidel After Elidel
19181716151413121110987654321
Patient no.
Patient no 20 had a score of 0, after Elidel® use
